# Hanmi Pharmaceutical

Source: https://onco.cc/companies/hanmi-pharmaceutical/  
OnCo record `hanmi-pharmaceutical` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Hanmi Pharmaceutical is one of South Korea's largest drug companies, known for its long-acting protein platform and for olmutinib, the third-generation EGFR inhibitor approved in Korea as Olita in 2016.

## Summary

Hanmi Pharmaceutical, founded in 1973 and based in Seoul, is a research-driven South Korean pharmaceutical company. Its LAPSCOVERY platform produced efpeglenatide and the neutropenia drug eflapegrastim (Rolvedon), and it has out-licensed several oncology candidates including the pan-RAF inhibitor belvarafenib and the FLT3 inhibitor tuspetinib. Olmutinib (HM61713), a third-generation EGFR T790M inhibitor, received conditional approval in Korea in 2016; Boehringer Ingelheim returned its licence the same year after cases of severe skin toxicity.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Hanmi Pharm; 한미약품; KRX:128940
- Tags: drug-maker
- HQ: Seoul
- Type: pharma
- Website: https://www.hanmipharm.com/
- Ticker: KRX:128940

## Sources

- Official website: https://www.hanmipharm.com/

## Connected records

- drugs: [Olmutinib](https://onco.cc/drugs/olmutinib/)

---
JSON: https://onco.cc/api/v1/entities/hanmi-pharmaceutical.json